Version 1
: Received: 4 January 2024 / Approved: 4 January 2024 / Online: 4 January 2024 (11:35:28 CET)
Version 2
: Received: 8 January 2024 / Approved: 8 January 2024 / Online: 9 January 2024 (14:48:40 CET)
Hsu, Y.-F.; Lin, S.-P.; Chu, Y.-T.; Tsai, Y.-T.; Huang, J.-W.; Phoa, F.K.H.; Wu, R.-M. Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson’s Disease. Int. J. Mol. Sci.2024, 25, 3554.
Hsu, Y.-F.; Lin, S.-P.; Chu, Y.-T.; Tsai, Y.-T.; Huang, J.-W.; Phoa, F.K.H.; Wu, R.-M. Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson’s Disease. Int. J. Mol. Sci. 2024, 25, 3554.
Hsu, Y.-F.; Lin, S.-P.; Chu, Y.-T.; Tsai, Y.-T.; Huang, J.-W.; Phoa, F.K.H.; Wu, R.-M. Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson’s Disease. Int. J. Mol. Sci.2024, 25, 3554.
Hsu, Y.-F.; Lin, S.-P.; Chu, Y.-T.; Tsai, Y.-T.; Huang, J.-W.; Phoa, F.K.H.; Wu, R.-M. Plasma miR-203a-3p as a Novel Predictor of Dementia in Patients with Parkinson’s Disease. Int. J. Mol. Sci. 2024, 25, 3554.
Abstract
Early detection of cognitive decline and in-time non-pharmacological management or drug therapy are extremely important in providing care for Parkinson’s disease with dementia (PDD). In this study, we firstly conducted a discovery study to identify 6 plasma microRNAs that may differentiate PD with or without mild cognitive impairment via NGS sequencing. Total 120 participants were further recruited in validation cohort and divided into 4 subgroups, including normal controls (HC), PD with no dementia (PDND), PD with mild cognitive impairment (PD-MCI) and PDD. Among the 6 candidates, miR-203a-3p was successfully detected in the plasma of the validation cohort using droplet digital PCR (ddPCR). Our results showed that the ratio of miR-203a-3p/miR-16-5p observed in PDD was significantly increased compared to PD-MCI (p < 0.001) and PDND (p = 0.041). Moreover, the ratio of miR-203a-3p/miR-16-5p showed a significant correlation with MoCA scores (r = -0.237, p = 0.024) in patients with PD (PwP). The ROC curve of the logistic regression model, consisting variates of age, the ratio of miR-203a-3p/miR-16-5p and the score of UPDRS III, also demonstrated an average AUC of 0.883 by 5-fold cross-validation. In conclusion, the ratio of miR-203a-3p/miR-16-5p may serve as a potential biomarker for distinguishing cognitive dysfunction from PwP.
Keywords
Plasma Biomarker; MicroRNA; Parkinson’s Disease; Cognitive decline; Droplet digital PCR
Subject
Biology and Life Sciences, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.